Nuvectis Pharma Inc.
5.48
-0.16 (-2.84%)
At close: Jan 15, 2025, 2:29 PM

Company Description

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology.

It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases.

The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Nuvectis Pharma Inc.
Nuvectis Pharma Inc. logo
Country United States
IPO Date Feb 4, 2022
Industry Biotechnology
Sector Healthcare
Employees 13
CEO Ron Bentsur M.B.A.

Contact Details

Address:
1 Bridge Plaza
Fort Lee, New Jersey
United States
Website https://www.nuvectis.com

Stock Details

Ticker Symbol NVCT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001875558
CUSIP Number 67080T108
ISIN Number US67080T1088
Employer ID 86-2405608
SIC Code 2834

Key Executives

Name Position
Ron Bentsur M.B.A. Co-Founder, Chairman, Chief Executive Officer & President
Dr. Enrique Poradosu Ph.D. Co-Founder, Executive Vice President, Chief Scientific & Business Officer
Michael Carson CPA Vice President of Finance
Shay Shemesh Co-Founder, Executive Vice President, Chief Development & Operations Officer

Latest SEC Filings

Date Type Title
Jan 03, 2025 4 Filing
Jan 03, 2025 4 Filing
Jan 03, 2025 4 Filing
Jan 03, 2025 4 Filing
Jan 03, 2025 S-8 Filing
Dec 26, 2024 4 Filing
Dec 16, 2024 4/A [Amend] Filing
Dec 16, 2024 4 Filing
Nov 20, 2024 4 Filing
Nov 18, 2024 4 Filing